Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

hTERT-derived peptide vaccine - Invectys

Drug Profile

hTERT-derived peptide vaccine - Invectys

Alternative Names: Human telomerase reverse transcriptase peptide-based vaccine - Invectys; UCP2-UCP4 vaccine - Invectys; UCPVax

Latest Information Update: 04 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Invectys
  • Developer Institut Pasteur; Regional and University Hospital of Besancon
  • Class Cancer vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Glioblastoma

Most Recent Events

  • 02 Jun 2023 Efficacy and adverse events data from a phase I/II trial in Glioblastoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 07 Dec 2022 hTERT-derived peptide vaccine is still in phase II trials for in Non-small c ell lung cancer France (NCT04263051)
  • 09 Sep 2020 Phase-II clinical trials in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater, Combination therapy) in France (SC) (NCT04263051)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top